SBioMedics Participates in JP Morgan Healthcare Conference... Actively Promotes Technology

Esbiomedics, a regenerative medicine research and development company, has been invited to the '2024 JP Morgan Healthcare Conference,' paving the way for the technology transfer of its Parkinson's disease cell therapy.

[Image source=Esbiomedics]

Esbiomedics announced on the 26th that it will participate in the JP Morgan Healthcare Conference held in San Francisco, USA, from January 8 to 11 next year. The JP Morgan Healthcare Conference is the world's largest healthcare industry investment event, gathering about 14,000 participants from 1,500 global healthcare companies and investment firms across more than 50 countries annually. A representative from Esbiomedics stated, "We attended the 'Cell & Gene Meeting on the Mesa' last October, where we presented the mechanism of action and efficacy of our Parkinson's disease treatment," adding, "This event attracted significant interest from global pharmaceutical companies, leading to our participation in this year's JP Morgan Healthcare Conference."

Esbiomedics' TED-A9 is a Parkinson's disease cell therapy developed to fundamentally cure Parkinson's by producing midbrain-specific dopamine neural progenitor cells at a high yield from embryonic stem cells. The efficacy tests and research results on the mechanism of action of TED-A9 were recently published in 'Cell Stem Cell' (IF=23.9), the leading journal in stem cell research. The study confirmed the 'successful production of the highest yield of dopamine neurons from clinical-grade embryonic stem cells' and 'safety and efficacy in large-scale preclinical animal experiments.' Additionally, the clinical trials of TED-A9 are planned to complete administration to all subjects by the first half of next year.

At the JP Morgan Healthcare Conference, Esbiomedics plans to actively engage in technology exchanges and business cooperation discussions with numerous global pharmaceutical and biotech companies.

An Esbiomedics representative said, "We plan to thoroughly explain the areas of interest and questions from global pharmaceutical companies and actively promote our Parkinson's disease treatment currently in clinical trials," adding, "Discussions related to future technology transfers and global joint research plans will also be intensified."

This content was produced with the assistance of AI translation services.